Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study | Zendy

Guillaume Cartron | Zendy; Zhaoyang Lu | Zendy; Marion Baudard | Zendy; Tarik Kanouni | Zendy; Valérie Rouille | Zendy; Philippe Quittet | Zendy; Bernard Klein | Zendy; JeanFrançois Rossi | Zendy

Open Access

Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study

Author(s) -

Guillaume Cartron,

Zhaoyang Lu,

Marion Baudard,

Tarik Kanouni,

Valérie Rouille,

Philippe Quittet,

Bernard Klein,

JeanFrançois Rossi

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2007.13.7729

Subject(s) - medicine , follicular lymphoma , rituximab , follicular phase , granulocyte colony stimulating factor , granulocyte macrophage colony stimulating factor , lymphoma , granulocyte , cancer research , colony stimulating factor , oncology , immunology , cytokine , chemotherapy , haematopoiesis , stem cell , biology , genetics

We hypothesized that granulocyte-macrophage colony-stimulating factor (GM-CSF) could potentiate the clinical activity of rituximab given its individual and cooperative effects on Fc gamma RIIa- and Fc gamma RIIIa-expressing cells. A phase II clinical study combining GM-CSF and rituximab was initiated in patients with relapsed follicular lymphoma (FL) to determine the clinical and biologic responses, as well as safety of the combination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research